NASDAQ$TRML
Tourmaline Bio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2024 and outlined recent business highlights.
Tourmaline Bio reported a net loss of $20.2 million for the third quarter of 2024. Cash, cash equivalents and investments were $314.4 million as of September 30, 2024, providing cash runway into 2027.
- On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025.
- Assembled Cardiovascular Scientific Advisory Board (CV SAB) in October 2024.
- Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024.
- Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027.
Headline financials
Revenue & EPS history
Tourmaline Bio · Revenue · Quarterly
$87K
Forward guidance
Tourmaline anticipates that its current cash, cash equivalents and investments will provide cash runway into 2027, funding its operations through key pacibekitug data readouts in TED and cardiovascular disease and providing the opportunity to expand development efforts into additional indications.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q3 2024
+0.7%
Avg return
Earnings day
-5.0%
Avg return
5 days after
+13.7%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+11.6%
Q4 2023
Best reaction
-9.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +3.8% | +3.1% | +122.3% | |
| Q1 2025 | +4.6% | +9.9% | +26.5% | |
| Q4 2024 | -2.8% | -4.8% | -1.4% | |
| Q3 2024 | +5.0% | -4.9% | -5.6% | |
| Q2 2024 | +2.0% | +4.6% | +12.2% | |
| Q1 2024 | -0.6% | -4.8% | +2.6% | |
| Q4 2023 | +11.6% | -38.1% | -60.9% | |
| Q3 2023 | -1.2% | — | — | |
| Q2 2023 | +1.3% | — | — | |
| Q1 2023 | -8.0% | — | — | |
| Q4 2022 | +2.8% | — | — | |
| Q3 2022 | +7.0% | — | — | |
| Q2 2022 | -9.7% | — | — | |
| Q1 2022 | +3.1% | — | — | |
| Q4 2021 | +4.6% | — | — | |
| Q3 2021 | -7.0% | — | — | |
| Q2 2021 | -5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro